Abstract
Paclitaxel-induced peripheral neuropathy not only reduces patient quality of life but also significantly interferes with the completion of cancer chemotherapy. In this study, we investigated the benefits and adverse events in 31 patients who received pregabalin for the treatment of paclitaxel : induced peripheral neuropathy between October 2010 and February 2012. In 27 (87.1%) of 31 patients who received pregabalin for peripheral neuropathy induced by paclitaxel, the neuropathy did not worsen to Grade 3, and paclitaxel chemotherapy could be continued. Drowsiness was a common adverse event associated with pregabalin (41.9%). These results suggest that pregabalin administration might prevent paclitaxel-induced peripheral neuropathy from worsening and consequently lead to improved chemotherapy completion rates. Moreover, it seems that pharmacists should monitor the severity of peripheral neuropathy and actively participate in planning treatment that includes the management of adverse events associated with pregabalin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.